Login / Signup

Safety, Stability and Pharmacokinetic Properties of (super)Factor Va, a Novel Engineered Coagulation Factor V for Treatment of Severe Bleeding.

Andrew J GaleVikas BhatJean-Luc PellequerJohn H GriffinLaurent O MosnierAnnette Von Drygalski
Published in: Pharmaceutical research (2016)
FVa has an appropriate safety and stability profile for further preclinical development as a prohemostatic against severe bleeding.
Keyphrases
  • atrial fibrillation
  • early onset
  • stem cells
  • cell therapy